Cellectis - ADR opened higher at $1.40, compared with its previous close of $1.38. In the last trading session, the stock traded between $1.29 and $1.40. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Cellectis - ADR is now worth
$ 12.96
Resulting in a loss of
$ 87.04 (87.04%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
25%
Hold
50%
Sell
25%
Markets Today
Today's Change
$-0.04 (-2.90%)
Day High
$1.40
Day Low
$1.29
Day Open
$1.40
Prev Close
$1.38
Volume
39,001
1W Return
16.52%
1M Return
14.92%
3M Return
-52.90%
6M Return
-66.33%
1Y Return
-63.98%
Fundamentals
Market Cap ($ Mn)
97
PE Ratio
-
PB Ratio
8.34
PEG Ratio
-
ROE
-64.90%
ROCE
-35.46%
EPS (TTM)
$-0.22
Investment Returns
1 Week
16.52%
1 Month
14.92%
3 Months
-52.90%
6 Months
-66.33%
9 Months
-63.29%
Financials
Quarterly
All values in $ Mn
10.7
Mar 25
16.7
Jun 25
35.2
Sep 25
10.4
Dec 25
5.8
Mar 26
5.2
Jun 26
Updates
10Nov
Cellectis sets Nov 12 date for Q3 2026 financial results release
Cellectis will release Q3 2026 financial results on November 12, 2026. Investor conference call scheduled for November 13, 2026 at 8:00 am ET. Results cover the quarter ending September 30, 2026.
3 days ago
23Sep
Pomerantz probes Cellectis as sixth firm investigates fraud claims
Pomerantz LLP initiates investigation into Cellectis S.A. securities practices. Share price fell 40.97% to $1.83 following CAR-T program halt. Sixth law firm joins existing probes into potential federal securities violations. Company pivots to in vivo gene editing due to limited cash resources.
1mo ago
14Sep
Cellectis pivots to in vivo gene editing, exits cell therapies
Cellectis pivots to in vivo gene editing, exiting CAR-T therapies. Shares fell 27.42% following the September 11 strategic announcement. Cash runway extended to H2 2028 via resource reallocation. Focus shifts to .HEAL-101 and .HEAL-201 for dyslipidemia treatment.
1mo ago
2Sep
Cellectis to present at five global healthcare investor conferences
Cellectis to participate in five global healthcare investor conferences in 2026. Presentation scheduled at Baird 2026 Global Healthcare Conference on September 15. Management available for meetings at Wells Fargo, Barclays, Stifel, and Jefferies events. Webcasts of presentations to be hosted on company website.
2mo ago
7Aug
Cellectis Q2 adjusted EPS beats estimate as sales miss target
Cellectis delivered a Q2 adjusted EPS beat of $(0.19) against a $(0.27) estimate, despite a significant revenue miss of $6.904 million versus $13.225 million. The company's cash position stands at $169 million, supporting operations through Q4 2027. Key pipeline milestones include FDA RMAT designation for lasme-cel and promising Phase 1 data for eti-cel.
3mo ago
31Jul
Cellectis Q2 Results: Financials due August 6 after close
Cellectis will announce its Q2 2026 financial results on August 6, 2026, after market close. The company will not hold a conference call. Details will be posted on the investor relations website.
